Latest Cellular and molecular biology biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

The cellular atlas of the human tonsil, a key to the understanding of the immune system and diseases such as leukaemias and lymphomas

by Fundació Clínic per a la Recerca Biomèdica

3 months ago
tonsil, secondary lymphoid organs, “Townsil”, leukaemias, lymphomas

The research provides the most comprehensive cellular map to date of the human tonsil, increasing our understanding of immune response to disease, and perception of immune system related diseases such...

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

by Ysios Capital

3 months ago
NRTX-1001, Neurona Therapeutics, mesial temporal lobe epilepsy (MTLE)

Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-...

Un 'interruptor' para una terapia génica más segura

by CIMA - Centro de Investigación Médica Aplicada

3 months ago
terapia de linfocitos T (CART)

Investigadores del Cima Universidad de Navarra han identificado un ácido ribonucleico (ARN) que permitiría modular la terapia génica contra el cáncer u otras patologías. Estos resultados orientan...

Conectan la mayor susceptibilidad de las mujeres a las enfermedades autoinmunes con la inactivación del cromosoma X

by Revista Genética Médica

3 months ago
Xist, cromosoma X

La inactivación del cromosoma X contribuye a la mayor incidencia de enfermedades autoinmunes en mujeres, señala un estudio que abre posibles estrategias para el diagnóstico temprano de estas enferm...

Innovative immunotherapy-based strategy to combat severe antibiotic-resistant infections

by Fundació Bosch i Gimpera

3 months ago
Antibiotic

Researchers are taking part in a new project with an innovative approach based on immunotherapy to treat serious infections that do not respond to antimicrobials.

The analysis of biological networks allows understanding the complexity of multiple sclerosis

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

3 months ago
MK03, multiple sclerosis

An international study has used a computational biology tool that, by analysing a multitude of biological data from multiple sclerosis patients ranging from genetic information to the whole organism, ...

An anticancer drug opens a new path for the treatment of Parkinson’s

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

3 months ago
metabolite M324, Rucaparib, protein α-synuclein, Parkinson

The fact that M324 is capable of reducing the abnormal accumulation of α-synuclein in neurons derived from stem cells of a Parkinson’s patient, highlights the therapeutic potential of this metaboli...

Descubren el proceso mediante el cual las legumbres ayudan a reducir el riesgo de sufrir diabetes tipo 2

by Universitat Rovira i Virgili

2 months ago
huella metabolómica, legumbres

Hasta ahora no se había identificado la huella metabolómica de este alimento en relación a la enfermedad. La investigación la ha liderado un equipo de la URV-IISPV-CIBERobn

Identifican un gen relacionado los defectos cardíacos en el síndrome de Down

by Revista Genética Médica

2 months ago
gen DYRK1A, síndrome de Down

Investigadores del Instituto Francis Crick y el University College London señal gen DYRK1A como causante de los defectos cardíacos en el síndrome de Down y potencial diana para futuras terapias.

An ultrasound scan at the end of pregnancy allows serious neonatal complications to be avoided in babies at risk

by Hospital Sant Joan de Déu

2 months ago
RATIO37, cerebroplacental ratio (CPR), Doppler

A study conducted by SJD Barcelona Children's Hospital and Hospital Clínic de Barcelona has demonstrated that inducing labour at term in such cases reduces these complications and ICU admissions of t...

I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome

by Instituto de Investigación e Innovación Parc Taulí

2 months ago
Fragile X syndrome (FXS), CTH120

The Phase IIa study will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with FXS, the most common form of inherited intellectual disability without a specific treatment

Exploratory analysis from the phase III INTRIGUE study points to the promise of liquid biopsy in guiding patient selection for targeted therapy and personalized medicine in advanced GIST

by VHIO

2 months ago
gastrointestinal stromal tumor (GIST)

Results of exploratory research from the open-label phase III INTRIGUE clinical trial demonstrate the potential utility of circulating tumor DNA (ctDNA) next-generation sequencing (NGS)-based analysis...